Jonathan M. Rothberg

from Wikipedia, the free encyclopedia
Rothberg, 2008

Jonathan Marc Rothberg (* 1963 ) is an American scientist and entrepreneur. He was instrumental in the development of high throughput sequencing .

Education and academic career

Rothberg studied Chemical Engineering at Carnegie Mellon University , graduated with a BS degree and moved to Yale University , where he received an MS , M.Phil. and Ph.D. completed. Among other things, he was involved in the sequencing of the Neanderthal genome by Richard Green and Svante Pääbo and in the project The Watson Genome , the sequencing of the genome of James D. Watson (and thus one of the first individual human genomes after that of Craig Venter ) .

Awards and memberships

Jonathan Rothberg is a member of the National Academy of Engineering . In early 2016 he received the National Medal of Technology and Innovation .

Company formation

CuraGen

As a student at Yale, he founded the company CuraGen in 1991, which developed drugs against cancer , such as B. Belinostat (a histone deacetylase inhibitor for ovarian cancer) (Belinostat was sold to TopoTarget for $ 39 million in 2008 ), or glembatumumab vedotin for breast cancer . CuraGen also developed active ingredients against side effects from chemotherapy and against kidney inflammation . Together with Bayer AG , CuraGen identified drug targets against type 2 diabetes mellitus .

During his time at CuraGen, he published proteome maps of eukaryotic cells in Nature and Science . CuraGen was sold to CellDex in 2009 for $ 94.5 million.

454 Life Sciences

In 1999 Rothberg founded the company 454 Life Sciences , which developed one of the first next generation sequencing devices. 454 Life Sciences was sold to Roche Diagnostics in 2007 for $ 154.9 million .

Ion torrent

Rothberg founded Ion Torrent in 2007, which developed the technology of semiconductor sequencing .

Rothberg also founded the Rothberg Institute For Childhood Diseases , a non-profit organization dedicated to the research and control of tuberous sclerosis , and is co-founder of RainDance Technologies, which develops and markets microfluidic diagnostic devices and methods.

Publications

A list of Rothberg's publications and patents can be found at Jonathan M. Rothberg / Publications .

Web links

Individual evidence

  1. ^ "Genome of DNA Discoverer Is Deciphered NYT, June 1, 2007"
  2. ^ "National Academy of Engineering"
  3. ↑ Drugs.com: CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
  4. ↑ FierceBiotech: CuraGen Corporation (CRGN) Sells ownership of belinostat to TopoTarget A / S for Approximately $ 39 Million
  5. ↑ drugs.com: CuraGen to Present CR011-vcMMAE Data at ASCO
  6. ↑ clinicaltrials.gov: A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis
  7. ^ New York Times: Bayer and CuraGen in $ 1.5 Billion Pact to Develop Drugs
  8. ↑ fiercebiotech.com: Celldex acquires CuraGen for $ 94.5M
  9. ↑ Businessweek: "Jonathan M. Rothberg"
  10. ↑ "Ion Torrent Official Webpage" ( Memento of the original from November 6, 2012 in the Internet Archive ) Info: The archive link was automatically inserted and not yet checked. Please check the original and archive link according to the instructions and then remove this notice.  @1@ 2Template: Webachiv / IABot / www.iontorrent.com
  11. ↑ "Raindance Technologies Official Webpage"
personal data
SURNAME Rothberg, Jonathan M.
ALTERNATIVE NAMES Rothberg, Jonathan Marc
BRIEF DESCRIPTION American scientist
DATE OF BIRTH 1963